

# Remdesivir for the treatment of COVID-19: a living systematic review

doi: 10.5867/medwave.2020.11.8080

## Appendix 2 - Classification tab

### Coronavirus disease (COVID-19) Est

Search in this L-OVE

By PICO  [Advanced search BETA](#)

Prevention or treatment

Remdesivir

COVID-19

Evidence List | Methods and report | Matrix | Flow diagram | **Classification** | Comparison

Classification of references for: Remdesivir for COVID-19

Please select reference status

My classification pending

Please select classification

All

Search strategy:

[(coronavir\* OR coronavirus\* OR betacoronavir\* OR "beta-coronavirus" OR "beta-coronaviruses" OR "corona virus" OR "virus corona" OR "corono virus" OR "virus corono" OR "corono virus" OR hcov\* OR covid\* OR "2019-ncov" OR cv19\* OR "cv-19" OR "cv 19" OR "n-cov" OR ncov\* OR (wuhan\* and [virus OR viruses OR viral]) OR "2019-ncov-related" OR "cv-19-related" OR "n-cov-related" OR ("non-covid")) AND ((remdesivir\* OR "GS-5734" OR "GS 5734" OR G55734\* OR Vekury\*)) AND ((coronavir\* OR coronavirus\* OR betacoronavir\* OR "beta-coronavirus" OR "beta-coronaviruses" OR "corona virus" OR "virus corona" OR "corono virus" OR "virus corono" OR hcov\* OR covid\* OR "2019-ncov" OR cv19\* OR "cv-19" OR "cv 19" OR "n-cov" OR ncov\* OR (wuhan\* and [virus OR viruses OR viral]) OR sars\* OR sari\* OR "severe acute respiratory syndrome" OR mers\* OR "middle east respiratory syndrome" OR "middle-east respiratory syndrome" OR "2019-ncov-related" OR "cv-19-related" OR "n-cov-related" ) OR (coronavir\* OR coronavirus\* OR betacoronavir\* OR "beta-coronavirus" OR "beta-coronaviruses" OR "corona virus" OR "virus corona" OR "corono virus" OR "virus corono" OR hcov\* OR covid\* OR "2019-ncov" OR cv19\* OR "cv-19" OR "cv 19" OR "n-cov" OR ncov\* OR (wuhan\* and [virus OR viruses OR viral]) OR "2019-ncov-related" OR "cv-19-related" OR "n-cov-related" ) OR ("middle east respiratory syndrome" OR "middle-east respiratory syndrome" OR mers\*) OR ((sars\* OR sari\* AND (coron\* OR virus\* OR viral\* OR hcov\*))) OR ("severe acute respiratory syndrome" ) OR ("non-covid")) AND ((coronavir\* OR coronavirus\* OR betacoronavir\* OR "beta-coronavirus" OR "beta-coronaviruses" OR "corona virus" OR "virus corona" OR "corono virus" OR "virus corono" OR hcov\* OR covid\* OR "2019-ncov" OR cv19\* OR "cv-19" OR "cv 19" OR "n-cov" OR ncov\* OR (wuhan\* and [virus OR viruses OR viral]) OR sars\* OR sari\* OR "severe acute respiratory syndrome" OR mers\* OR "middle east respiratory syndrome" OR "middle-east respiratory syndrome" OR "2019-ncov-related" OR "cv-19-related" OR "n-cov-related" )

Total pending: 684

**Excluded**

Identification and Tracking of Antiviral Drug Combinations.

Year	2020
Journal	Viruses
Authors	lanevski A et al
DOI	10.3390/v12101178

Hide abstract  Show Keywords

Combination therapies have become a standard for the treatment for HIV and hepatitis C virus (HCV) infections. They are advantageous over monotherapies due to better efficacy, reduced toxicity, as well as the ability to prevent the development of resistant viral strains and to treat viral co-infections. Here, we identify new synergistic combinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), echovirus 1 (EVI), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1) in vitro. We observed synergistic activity of nelfinavir with convalescent serum and with purified neutralizing antibody 23G7 against SARS-CoV-2 in human lung epithelial Calu-3 cells. We also demonstrated synergistic activity of nelfinavir with EIDD-2801 or remdesivir in Calu-3 cells. In addition, we showed synergistic activity of vemurafenib with emetine, homoharringtonine, anisomycin, or cycloheximide against EV1 infection in human lung epithelial A549 cells. We also found that combinations of sofosbuvir with beqvirin or nicosamide are synergistic against HCV infection in hepatocyte-derived Huh-7.5 cells, and that combinations of monensin with lamivudine or tenofovir are synergistic against HIV-1 infection in human cervical T2M-bl cells. These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status.

Is this reference part of Remdesivir for COVID-19?